For example, activating BRAF mutations (e.g. V600E) have been associated with a benefit using vemurafenib in melanomas, but not in colorectal carcinomas due to the activation of EGFR pathway in colon cancer [23]. This evidence concerns the gene BRAF and colorectal carcinoma.